Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study

International Journal of Cardiology

Volumn 182, Issue , 2015, Pages 541-548

  Nakamura, Masato ^a   Isshiki, Takaaki ^b   Kimura, Takeshi ^c   Ogawa, Hisao ^d   Yokoi, Hiroyoshi ^e   Nanto, Shinsuke ^f   Takayama, Morimasa ^g   Kitagawa, Kazuo ^h   Ikeda, Yasuo ⁱ   Saito, Shigeru ^j  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TEIKYO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^f Nishinomiya Municipal Central Hospital   (Japan)

^g SAKAKIBARA HEART INSTITUTE   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ WASEDA UNIVERSITY   (Japan)

^j SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

more..

Author keywords

Acute coronary syndrome; Clopidogrel; CYP2C19; Major adverse cardiovascular event; Platelet reactivity; Prasugrel

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; P2RY12 PROTEIN, HUMAN; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; BLOOD; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; PROCEDURES; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC;

ACUTE CORONARY SYNDROME; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; ROC CURVE; TICLOPIDINE;

EID: 84947201512     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.026     Document Type: Article

References (29)

1. J.L. Anderson, R.S. Wright, C.D. Adams, and et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 60 2012 645 681
2. F.G. Kushner, M. Hand, S.C. Smith Jr., and et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
3. 12 inhibitors Circulation 121 2010 171 179
4. J.T. Brandt, S.L. Close, S.J. Iturria, and et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J. Thromb. Haemost. 5 2007 2429 2436
5. J.S. Hulot, A. Bura, E. Villard, and et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
6. J.L. Mega, S.L. Close, S.D. Wiviott, and et al. Cytochrome P-450 polymorphisms and response to clopidogrel N. Engl. J. Med. 360 2009 354 362
7. L. Bonello, U.S. Tantry, R. Marcucci, and et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J. Am. Coll. Cardiol. 56 2010 919 933
8. F. Mangiacapra, G. Patti, E. Barbato, and et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study JACC Cardiovasc. Interv. 5 2012 281 289
9. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schömig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J. Am. Coll. Cardiol. 56 2010 317 318
10. G.W. Stone, B. Witzenbichler, G. Weisz, and et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study Lancet 382 2013 614 623
11. S.D. Wiviott, E. Braunwald, C.H. McCabe, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
12. L. Wallentin, R.C. Becker, A. Budaj, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057
13. H. Yokoi, T. Kimura, T. Isshiki, H. Ogawa, and Y. Ikeda Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention Thromb. Res. 129 2012 623 628
14. S. Saito, T. Isshiki, T. Kimura, and et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome - the PRASFIT-ACS study Circ. J. 78 2014 1684 1692
15. R. Marcucci, A.M. Gori, R. Paniccia, and et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay Circulation 119 2009 237 242
16. M.J. Price, P.B. Berger, P.S. Teirstein, and et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
17. D. Trenk, G.W. Stone, M. Gawaz, and et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents J. Am. Coll. Cardiol. 59 2012 2159 2164
18. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K.L. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N. Engl. J. Med. 356 2007 1020 1029
19. T. Cuisset, C. Frere, J. Quilici, and et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes Thromb. Haemost. 97 2007 282 287
20. G. Parodi, R. Marcucci, R. Valenti, and et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
21. J.P. Collet, T. Cuisset, G. Range, and et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N. Engl. J. Med. 367 2012 2100 2109
22. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J. Am. Coll. Cardiol. 52 2008 1128 1133
23. M.J. Price, S. Endemann, R.R. Gollapudi, and et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J. 29 2008 992 1000
24. S.G. Ahn, S.H. Lee, J.H. Yoon, and et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction JACC Cardiovasc. Interv. 5 2012 259 267
25. P.A. Gurbel, D. Erlinge, E.M. Ohman, and et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 308 2012 1785 1794
26. S.S. Brar, J. ten Berg, R. Marcucci, and et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J. Am. Coll. Cardiol. 58 2011 1945 1954
27. D. Trenk, W. Hochholzer, M.F. Fromm, and et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J. Am. Coll. Cardiol. 51 2008 1925 1934
28. J.L. Mega, S.L. Close, S.D. Wiviott, and et al. Cytochrome P-450 polymorphisms and response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
29. J.S. Jang, K.I. Cho, H.Y. Jin, and et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel Am. J. Cardiol. 110 2012 502 508